Eligard (leuprorelin acetate) | For UK Healthcare Professionals
 EXPLORE ELIGARD’S FLEXIBLE DOSING
The versatility of two
subcutaneous doses
to meet the needs
of patients and clinical practice1,2
ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.1
ELIGARD: an ADT that offers a 6-month subcutaneous dose
in both Primary and Secondary Care1
ELIGARD is available in 3 and 6-month doses for subcutaneous injection and a fine needle with low injection volume1,3
22.5 mg
3-month
formulation
45 mg
6-month
formulation
Longer-lasting formulations provide
flexibility for patients, with up to 6 months of treatment-free management4
Based on 200 face-to-face interviews of patients with prostate cancer and receiving LHRH agonist treatment in five European countries (France, Germany, Italy, the Netherlands, Spain).5
Offering multiple injection sites gives
patients greater flexibility vs a single site*1
Examples of flexible administration options1
Upper Arm
Abdomen
Upper Buttock
Thigh
*Injection sites comprise locations with adequate amounts of subcutaneous tissue that
do not have excessive pigment, nodules, lesions, or hair and have not recently been used.1
Convenient storage and handling
READY-TO-GO
You can keep ELIGARD for up to
4 weeks at room temperature
(<25°C), so it is ready for use
whenever you need it1
LONGER TERM STORAGE
Store ELIGARD in the refrigerator
(2–8°C) in its original packaging.
Acclimatise at room temperature
for approximately 30 minutes
before administration1
Pre-Connected Syringe System1
Simply
click, mix & inject1
1. CLICK
Grasp the connector button with your fingers and press until you hear a click. The two syringes are now perfectly aligned with each other.
2. MIX
Hold the syringes in a horizontal position and slowly and gently transfer the liquid from syringe A to the powder of syringe B.
Without bending the syringe system, gently and slowly go back and forth for 60 cycles until obtaining a homogeneous and viscous solution.â€
When mixed, hold the syringes vertically and empty syringe A into syringe B.
Remove the connector (with syringe A) from syringe B.
†A single cycle represents 1 push of syringe A and 1 push of syringe B. Sixty cycles are performed during mixing
Eligard should not be administered if it is not prepared using the proper technique as lack of clinical efficacy
may occur due to incorrect reconstitution of the product.
3. INJECT
Turn the needle with safety shield onto syringe B, without tightening too much.
Small air bubbles should not be removed.
Select an appropriate injection site and cleanse it with an alcohol swab.
Administer ELIGARD immediately by grabbing the skin around the injection site, inserting the needle at a 90° angle, releasing the skin, and slowly injecting the syringe contents until syringe is completely empty.1
Watch the full ELIGARD
administration video here
94% (24/26)
of healthcare
professionals said they would highly recommend the Eligard device to colleagues6
From a hands-on early adopter workshop conducted with 26 HCPs (17 urologists and 9 medical assistants) evaluating the Eligard device under real‑world conditions.6
with the risk of potential disease progression
- ELIGARD Summary of Product Characteristics.
- Sartor O. Eur Urol Suppl. 2006;5:905–910.
- Center for Drug Evaluation and Research. ELIGARD 45 mg Injection Suspension Approval Package. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021731s000_Eligard_AdminCorres.pdf. (Last Accessed: July 2025).
- Ouzaid I, et al. Progrès en Urologie. 2011;21:866–87.
- Schulman C. BJU Int. 2007;100 (Suppl. 1):6–11.
- Pickl, S. Blickpunkt Medizin. 2023 (Sponsored by Recordati Pharmaceuticals Ltd).
Information on the processing of personal data for Medical Information,Â
Safety Reporting and Product Quality Complaint – click here
UK-ELIGA-0052 | September 2026 © 2026 Recordati
